Cancer reports最新文献

{"title":"Precision Nutrition as the Concept of Dietary and Nutritional Interventions for Patients With Malignancies: A Narrative Literature Review and Perspectives","authors":"Ken Yamaguchi,&nbsp;Koji Yamanoi,&nbsp;Jumpei Ogura,&nbsp;Ayami Koike,&nbsp;Maki Umemiya,&nbsp;Nozomi Higashiyama,&nbsp;Kazuhiro Kou,&nbsp;Yoshihide Inayama,&nbsp;Rin Mizuno,&nbsp;Taito Miyamoto,&nbsp;Mana Taki,&nbsp;Ryusuka Murakami,&nbsp;Junzo Hamanishi,&nbsp;Mandai Masaki","doi":"10.1002/cnr2.70702","DOIUrl":"10.1002/cnr2.70702","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Dietary and nutritional interventions have gained popularity among patients with cancer undergoing treatment due to the high cost of medical treatment and increased health awareness. Diet, nutrition, psychological stress, and adverse events during treatment have a significant impact on the quality of life of patients with cancer. This study aimed to review published studies and guidelines on diet and exercise for cancer survivors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Recent Findings</h3>\u0000 \u0000 <p>Although several academic associations have published guidelines on the impact of diet and nutrition on cancer treatment, physicians typically do not consider this impact.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study summarizes recent findings on the effects of diet and nutrition, particularly fasting-mimicking diet, on the prognosis and adverse events of chemotherapy. Furthermore, this study outlines future perspectives on cancer treatment based on “Precision Nutrition” and “Molecular Precision Medicine”.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 10","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13641975/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Talc Use and Risk of Cancer: An Umbrella Review and Overlapped Analysis","authors":"Frank Mayta-Tovalino,&nbsp;Miguel Cabanillas-Lazo,&nbsp;Carlos Quispe-Vicuña,&nbsp;Fran Espinoza-Carhuancho,&nbsp;Adrian V. Hernandez","doi":"10.1002/cnr2.70705","DOIUrl":"10.1002/cnr2.70705","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This umbrella review aimed to systematically synthesize and critically appraise the available evidence from systematic reviews and meta-analyses evaluating the association between talc exposure and cancer risk in humans.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This umbrella review was conducted in accordance with the PRIOR guidelines and registered in PROSPERO. A comprehensive search of PubMed, Embase, Scopus, Web of Science, and Epistemonikos was performed up to October 2024 without language or date restrictions. Eligible studies were systematic reviews evaluating any type of talc exposure in humans. Study selection and data extraction were performed independently, and risk of bias was assessed using the AMSTAR-2 tool.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Nine systematic reviews were included, eight combining cohort and case–control studies and one restricted to cohort studies. Cosmetic talc exposure was the most frequently investigated, with most reviews focused on ovarian cancer. Moderate overlap of study populations (9.2%) was identified, primarily related to Boon et al. Based on AMSTAR-2, confidence in the evidence was moderate in one review and critically low in seven, with frequent methodological shortcomings such as lack of protocol registration and unclear study exclusions. For occupational exposure, elevated risks were observed for overall cancer (RR 1.21; 95% CI 1.03–1.42) and colorectal cancer (SIR 1.59; 95% CI 1.07–2.26), while no increased risk was found for other cancer types. Four of five systematic reviews evaluating cosmetic talc exposure and ovarian cancer reported a statistically significant association with increased ovarian cancer risk, whereas one review found no statistically significant association. However, confidence in the results of the reviews included was predominantly low or critically low, reflecting important methodological limitations, including concerns regarding risk-of-bias assessment and reporting. Overall, the evidence supporting an association between cosmetic talc exposure and ovarian cancer was of limited confidence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>There is limited evidence from systematic reviews regarding the association of exposure to cosmetic talc with an increased risk of developing ovarian cancer. Therefore, the results of the systematic reviews should be regarded as suggestive, rather than definitive, and further studies are required to demonstrate a causal relationship.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 10","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13638487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Race and Socioeconomic Status are Predictors of Survival in Patients With Metastatic Bone Disease Secondary to Breast Cancer","authors":"Ashley Castan,&nbsp;Rosamaria Dias,&nbsp;Amog Mysore,&nbsp;David Herz,&nbsp;Katie Gotoff,&nbsp;Yazan Kadkoy,&nbsp;Kathleen Beebe,&nbsp;Joseph Benevenia,&nbsp;Joseph Ippolito","doi":"10.1002/cnr2.70689","DOIUrl":"10.1002/cnr2.70689","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;With implementation of early detection screening methods and advances in medical treatment, there have been improvement in outcomes for patients with breast cancer. Despite this, studies have suggested potential differences in outcomes amongst various racial and ethnic groups. To our knowledge, no study has evaluated if race and demographic characteristics impact survival outcomes in patients with breast cancer metastases to the bone.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Aims&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We sought to answer the following questions: (1) Does race, demographic, and tumor characteristics alter survival outcomes in patients with breast metastases to the bone? (2) When stratifying by income and treatment, does race influence survival outcomes in patients with breast metastases to the bone?&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods and Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The surveillance, epidemiology, and end results (SEER) 2016 to 2021 database was reviewed for patients with a diagnosis of breast cancer with metastases to the bone &lt;i&gt;N&lt;/i&gt; = 11 833. Patients with known primary breast cancer, known hormone receptor status, known metastasis to bone, known treatment regiment, and no additional cancer diagnoses were included. Using variables within the database, this study collected information on demographics and tumor characteristics. Multivariate analyses were conducted to determine associations between race and other demographic, clinical, and prognostic factors. Kaplan–Meier survival curves were utilized to evaluate outcome by race. Annual household income below $75 000 (hazard ratio 1.111 [95% confidence interval (CI): 1.047–1.178, &lt;i&gt;p&lt;/i&gt; &lt; 0.001]), age over 65 years old (hazard ratio 1.1150 [95% CI: 1.084–1.220, &lt;i&gt;p&lt;/i&gt; &lt; 0.001]), and race (black) (hazard ratio 1.256 [95% CI: 1.161–1.359, &lt;i&gt;p&lt;/i&gt; &lt; 0.001]) were independent risk factors for decreased survival likelihood. Surgery (hazard ratio 0.554 [95% CI: 0.507–0.606, &lt;i&gt;p&lt;/i&gt; &lt; 0.001]), chemotherapy (hazard ratio 0.421 [95% CI: 0.397–0.446, &lt;i&gt;p&lt;/i&gt; &lt; 0.001]), and radiation (hazard ratio 0.940 [95% CI: 0.885–0.998, &lt;i&gt;p&lt;/i&gt; &lt; 0.05]), were independent factors that increased survival. At 12-month follow-up (hazard ratio 1.211 [95% CI: 1.091–1.345, &lt;i&gt;p&lt;/i&gt; &lt; 0.001]) and 5-year follow-up (hazard ratio 1.256 [95% CI: 1.161–1.359, &lt;i&gt;p&lt;/i&gt; &lt; 0.001]) black women had decreased survival likelihood compared to all other races. When patients were stratified by annual household income greater than $75 000, regardless of treatment, black women had decreased survival likelihood in patients younger then 65 years old (hazard ratio 1.242 [95% CI: 1.117–1.381, &lt;i&gt;p&lt;/i&gt; &lt; 0.001])","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 10","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13638486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pattern-Based P53 Immunohistochemistry Predicts Recurrence in Colorectal Liver Metastases Without Complete Pathologic Response After Neoadjuvant Chemotherapy","authors":"Phat Thi Hong Ho,&nbsp;Duy Duc Nguyen,&nbsp;Vuong Dinh Thy Hao,&nbsp;Giang Huong Tran,&nbsp;Lam Viet Trung,&nbsp;Thinh Van Hoang,&nbsp;Hoang Bac Nguyen","doi":"10.1002/cnr2.70701","DOIUrl":"10.1002/cnr2.70701","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Aberrant p53 expression may have prognostic significance in colorectal cancer; however, its role in patients with colorectal liver metastases (CRLM) who receive neoadjuvant chemotherapy but do not achieve pathological complete response (pCR) remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>We evaluated whether aberrant p53 expression assessed by immunohistochemistry (IHC) predicts recurrence-free survival (RFS) in patients with CRLM receiving neoadjuvant FOLFOXIRI followed by resection without achieving pCR.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>A prospective cohort study was conducted on 39 patients with CRLM who met the inclusion criteria. All patients received neoadjuvant chemotherapy with the FOLFOXIRI regimen. Following surgical resection of both primary colorectal tumors and liver metastases, none of the patients achieved pCR. Immunohistochemistry was performed to assess p53 expression in resected liver metastasis specimens using a pattern-based interpretation model. RFS was analyzed using univariate and multivariate Cox proportional hazards models. Aberrant p53 expression was observed in 20 patients (51.3%). In univariate analysis, aberrant p53 expression (HR = 2.20; 95% CI: 1.02–4.71; <i>p</i> = 0.043), total tumor size &gt; 6 cm (HR = 5.62; 95% CI: 2.31–13.68; <i>p</i> &lt; 0.001), number of liver metastases &gt; 4 (HR = 4.41; 95% CI: 1.59–12.26; <i>p</i> = 0.004), and positive surgical margin (HR = 2.62; 95% CI: 1.16–5.91; <i>p</i> = 0.021) were significantly associated with recurrence. In multivariate analysis, aberrant p53 expression (HR = 3.78; 95% CI: 1.56–9.15; <i>p</i> = 0.003) and total tumor size &gt; 6 cm (HR = 5.23; 95% CI: 1.56–17.55; <i>p</i> = 0.007) remained independent prognostic factors for shorter RFS.cnr270701_RedLinePDF.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Aberrant p53 expression, as assessed by immunohistochemistry on post-neoadjuvant chemotherapy specimens, is an independent prognostic factor for early recurrence in patients with CRLM who did not achieve pCR. Together with total tumor size, aberrant p53 expression may serve as a useful marker for risk stratification and personalized postoperative treatment strategies in this high-risk patient population.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 10","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13633474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Behavior Change Interventions to Promote Healthy Lifestyles Among Adolescent and Young Adult Childhood Cancer Survivors: A Scoping Review.","authors":"C Gélinas-Gagné, K Bilodeau, N Guarascio, M Caru, H Coltin, D Curnier, L Desjardins, C Laverdière, V Marcil, R Santiago, S Vairy, S Sultan","doi":"10.1002/cnr2.70721","DOIUrl":"10.1002/cnr2.70721","url":null,"abstract":"<p><strong>Background: </strong>Adolescent and young adult childhood cancer survivors (AYA-CCS) face elevated risks of chronic health conditions and premature mortality further exacerbated by poor lifestyle behaviors including physical inactivity, poor nutrition, and substance use. Behavioral interventions are essential for supporting long-term health in this population; however, the evidence remains fragmented and unbalanced across lifestyle domains. This scoping review aimed to identify and describe behavioral interventions promoting healthy lifestyles among AYA-CCS, focusing on four domains (physical activity, nutrition, alcohol use, and tobacco use), and to map the behavior change techniques employed. Following the Joanna Briggs Institute methodology, a comprehensive search was conducted. Eligible studies targeted AYA-CCS aged 13-39 years and included interventions addressing at least one of the four behavioral domains. Records were published between 2005 and 2025. Data were extracted using the Template for Intervention Description and Replication (TIDieR) checklist and categorized according to the Behavior Change Wheel to identify intervention functions and sources of behavior change.</p><p><strong>Findings: </strong>The search identified 6170 records, 23 articles met inclusion criteria (representing 17 distinct interventions). Most interventions (76.5%) targeted physical activity. Education, enablement, and training were the most frequently used intervention functions, primarily addressing psychological capability and reflective motivation. Strategies targeting automatic motivation, physical capability, or social opportunity were far less common. Only three multi-domain interventions were identified.</p><p><strong>Conclusion: </strong>Current behavior change interventions for AYA-CCS are dominated by physical activity programs, with limited attention to nutrition, alcohol, and tobacco use. While many interventions were theory-informed, important gaps remain in fidelity reporting, multi-behavioral targeting, and explaining mechanisms of change.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 10","pages":"e70721"},"PeriodicalIF":2.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149219954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic significance of tumor microenvironment assessed by machine learning algorithm in surgically resected non-small cell lung cancer.","authors":"Yukihiro Terada, Mitsuhiro Isaka, Akira Ono, Takuya Kawata, Masakuni Serizawa, Keita Mori, Koji Muramatsu, Kiyoshi Tone, Hirotsugu Kenmotsu, Keiichi Ohshima, Kenichi Urakami, Takeshi Nagashima, Masatoshi Kusuhara, Yasuto Akiyama, Takashi Sugino, Toshiaki Takahashi, Yasuhisa Ohde","doi":"10.1002/cnr2.1926","DOIUrl":"10.1002/cnr2.1926","url":null,"abstract":"<p><strong>Background: </strong>A methodology to assess the immune microenvironment (IME) of non-small cell lung cancer (NSCLC) has not been established, and the prognostic impact of IME factors is not yet clear.</p><p><strong>Aims: </strong>This study aimed to assess the IME factors and evaluate their prognostic values.</p><p><strong>Methods and results: </strong>We assessed CD8⁺ tumor-infiltrating lymphocyte (TIL) density, forkhead box protein P3⁺ (Foxp3⁺) TIL density, and programmed death receptor ligand-1 (PD-L1) tumor proportion score (TPS) using a machine-learning algorithm in whole-slide imaging (WSI). We dichotomized patients according to TIL density or TPS and compared their clinical outcomes. Between September 2014 and September 2015, 165 patients with NSCLC were enrolled in the study. We assessed IME factors in the epithelium, stroma, and their combination. An improvement in disease-free survival (DFS) was observed in the high CD8⁺TIL density group in the epithelium, stroma, and the combination of both. Moreover, the group with high PD-L1 TPS in the epithelium showed better DFS than that with low PD-L1 TPS. In the multivariate analysis, the CD8⁺TIL density in the combination of epithelium and stroma and PD-L1 TPS in the epithelium were independent prognostic factors (hazard ratio [HR] = 0.43; 95% confidence interval [CI] = 0.26-0.72; p = .001, HR = 0.49; 95% CI = 0.30-0.81; p = .005, respectively).</p><p><strong>Conclusion: </strong>Our approach demonstrated that the IME factors are related to survival in patients with NSCLC. The quantitative assessment of IME factors enables to discriminate patients with high risk of recurrence, who can be the candidates for adjuvant therapy. Assessing the CD8⁺TIL density in the combination of epithelium and stroma might be more useful than their individual assessment because it is a simple and time-saving analysis of TILs in WSI.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":" ","pages":"e1926"},"PeriodicalIF":2.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13659040/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71410732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Status and Predictors of Mortality Among Women With Breast Cancer in Southern Ethiopia: A Retrospective Cohort Study.","authors":"Bitsiet Desta, Tsion Zebdiwos Chema, Sophonias Sisay, Mulualeme Nigusie, Bargude Balta","doi":"10.1002/cnr2.70722","DOIUrl":"10.1002/cnr2.70722","url":null,"abstract":"<p><strong>Introduction: </strong>Breast cancer continues to be a leading cause of morbidity and mortality worldwide, with an especially severe impact in low-resource settings. In such contexts, delayed diagnosis, limited diagnostic capacity, and inadequate access to treatment contribute to poor survival outcomes. However, little is known about how these factors influence survival patterns specifically in southern Ethiopia, highlighting the need for locally generated data to guide interventions.</p><p><strong>Methodology: </strong>A hospital-based retrospective cohort study was conducted among 507 breast cancer patients attending selected hospitals in southern Ethiopia. Data were collected by two trained BSc nurses using an Open Data Kit (ODK) tool. Descriptive statistics were presented using tables and graphs, while bivariable, and multivariable Cox regression models were used to identify independent predictors of survival.</p><p><strong>Results: </strong>A total of 507 medical records were reviewed, of which 492 eligible women were included in the final analysis. The overall survival rates were 54.5% at 2 years and 23.9% at 3 years. In multivariable Cox regression analysis, advanced stage had a higher hazard of death (AHR = 1.73, 95% CI: 1.19-2.51). Poor NPI was also associated with increased mortality (AHR = 2.30, 95% CI: 1.50-5.10). Patients with an NLR < 3 had a lower hazard of death (AHR = 0.68, 95% CI: 0.47-0.97), as did those who received hormonal therapy (AHR = 0.64, 95% CI: 0.44-0.92).</p><p><strong>Conclusion: </strong>Advanced-stage disease and poorer NPI were associated with a higher hazard of death from any cause, while lower NLR and hormonal therapy were associated with better overall survival. Strengthening early diagnosis and ensuring appropriate treatment may improve overall survival among women with breast cancer in resource-constrained settings.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 10","pages":"e70722"},"PeriodicalIF":2.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13675522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149206575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential Modulation of WNT/β-Catenin Pathway-Associated Molecular Responses by Palmitate and Oleate in Lipid-Loaded HepG2 Cells.","authors":"Moayed Al-Haeri, Yaser Mohammadi, Roghiyeh Pashaei-Asl, Elham Bahreini","doi":"10.1002/cnr2.70703","DOIUrl":"10.1002/cnr2.70703","url":null,"abstract":"<p><strong>Background: </strong>Palmitate (PA) and oleate (OA), the predominant saturated and monounsaturated fatty acids, respectively, may differentially influence hepatic signaling. However, their individual and combined effects on WNT/β-catenin-related responses in HepG2 cells remain incompletely characterized.</p><p><strong>Methods: </strong>Human HepG2 cells were exposed to PA, OA, or a combined PA/OA treatment for 24 h. Cell viability was determined via MTT assay, while intracellular lipid droplet (LD) accumulation was evaluated using Oil Red O staining. Transcriptional alterations of canonical WNT/β-catenin cascade genes (WNT, CTNNB1, GSK-3β, TCF, LEF, Axin1, and Axin2) were analyzed by RT-qPCR. Protein expression levels of WNT, β-catenin, and Glypican-3 (GPC3) were evaluated to assess pathway activation.</p><p><strong>Results: </strong>Both fatty acids induced dose-dependent cytotoxicity and intracellular lipid accumulation, with the combined PA/OA treatment provoking the highest LD content. At the molecular level, palmitate predominantly activated the canonical cascade, significantly upregulating WNT, CTNNB1, TCF, and Axin2 mRNA, alongside elevated WNT, β-catenin, and GPC3 protein levels. Conversely, oleate selectively upregulated LEF and GSK-3β without coordinated canonical cascade activation, maintaining lower WNT and GPC3 protein expressions. Interestingly, co-treatment with PA/OA yielded intermediate molecular responses, partially attenuating palmitate-induced activation of WNT and Axin2, and facilitating a partial recovery of Axin1 expression.</p><p><strong>Conclusion: </strong>PA and OA differentially modulated WNT/β-catenin pathway-associated responses in lipid-loaded HepG2 cells. PA elicited a broader response involving WNT, CTNNB1, TCF, Axin2, WNT, and β-catenin, whereas OA produced a more selective response. Their combination partially attenuated PA-associated changes, highlighting fatty acid composition as a potential determinant of cellular responses to lipotoxic stress.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 10","pages":"e70703"},"PeriodicalIF":2.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13655650/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149163897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Periprocedural Wound Complication Risks in Cancer Pain Patients Following Targeted Cancer Therapy: A Retrospective Analysis.","authors":"Soun Sheen, Vishal Bansal, Xiaowen Sun, Jian Wang, Saba Javed","doi":"10.1002/cnr2.70664","DOIUrl":"10.1002/cnr2.70664","url":null,"abstract":"<p><strong>Background: </strong>In light of the increasing use of advanced operative procedures for cancer pain, it is crucial for pain physicians to understand the unique potential risks associated with multimodal cancer treatments.</p><p><strong>Aims: </strong>We aimed to characterize the periprocedural wound healing risk associated with newer targeted cancer therapies in cancer pain patients.</p><p><strong>Methods and results: </strong>A retrospective cohort study was conducted in patients 18 years or older undergoing operative procedures for cancer-related pain. The treatment group comprised patients on targeted cancer therapies, and the control group comprised patients not on these treatments. A generalized estimating equations model was used to compare the risk of wound-related complications between groups. A total of 195 encounters were identified in 150 patients. Wound-related complications occurred in 4/44 (9.1%) encounters in the treatment group and 3/151 (2.0%) in the control group. The treatment group had higher odds of wound-related complications (OR: 7.41, 95% CI: 1.36-40.40; p = 0.02). Higher BMI, diabetes, and concurrent steroid use also contributed to a higher risk of wound-related complications.</p><p><strong>Conclusions: </strong>Our study suggests that concurrent targeted cancer therapies may be associated with an increased risk of wound-related complications, although the estimate is imprecise given a heterogeneous cohort and a small number of events. It is essential for pain physicians to understand the potential risks associated with these cancer treatments and to collaborate with oncologists in the periprocedural period to optimize patient care.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 10","pages":"e70664"},"PeriodicalIF":2.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13668153/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of HRD Score With Efficacy of Neoadjuvant Short-Course Radiotherapy Plus Sequential Chemoimmunotherapy in pMMR Locally Advanced Rectal Cancer","authors":"Xin Ran,&nbsp;He Xiao,&nbsp;Peng Zhou,&nbsp;Juan He,&nbsp;Mengyuan Si,&nbsp;Xiuqiong Chen,&nbsp;Xiaona Su,&nbsp;Zhuo Chen,&nbsp;Jia Du,&nbsp;Xiaoyan Dai,&nbsp;Xiao Yang,&nbsp;Haode Shen,&nbsp;Zongsheng He,&nbsp;Fan Li,&nbsp;Mengxia Li,&nbsp;Chuan Chen","doi":"10.1002/cnr2.70708","DOIUrl":"10.1002/cnr2.70708","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Homologous recombination deficiency (HRD) has been reported to be associated with increased sensitivity to platinum-based treatment and radiotherapy in some solid tumors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>This study investigated the correlation between HRD score and treatment response to neoadjuvant short-course radiotherapy combined with sequential chemotherapy and tislelizumab in mismatch repair-proficient (pMMR) locally advanced rectal cancer (LARC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Thirty-two pMMR LARC patients from clinical trial NCT05515796 were enrolled. Pretreatment biopsy samples were analyzed for HRD scores and tumor immune microenvironment (TIME) gene expression profiles. Using receiver operating characteristic (ROC) analysis, patients were stratified into low (0–8), intermediate (9–37), and high (&gt; 37) HRD score groups to compare pathological complete response (pCR) rates. Abundance of immune cells and immune-related pathways were assessed with MCPcounter and single sample gene set enrichment analysis (ssGSEA) respectively and compared among the three HRD score groups. The entire cohort demonstrated pCR rate of 40.62% (13/32) with a median HRD score of 9 (range: 0–70). ROC analysis showed that HRD score as a continuous variable did not reach statistical significance in distinguishing pCR patients from non-pCR patients, nor did TMB and HR mutation. However, the proportion of categorized HRD score was significantly different between pCR and non-pCR groups (low, intermediate, high HRD score: 61.54%, 23.08%, 15.38% vs. 31.58%, 68.42%, 0%, <i>p</i> = 0.017). High-HRD tumors exhibited the highest CD8+ T-cell abundance followed by low-HRD and intermediate-HRD groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>HRD score may be associated with efficacy of neoadjuvant radioimmunotherapy in pMMR LARC patients, potentially mediated through enhanced CD8+ T-cell recruitment. These findings support precision patient selection, though mechanistic validation is required.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 10","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13630485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}